CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy

Tsicopoulos, Anne; LABALETTE, M.; AKOUM, H.; DUEZ, C.; WALLAERT, B.; DESSAINT, J. P.; TONNEL, A. B.

doi:10.1046/j.1365-2222.1996.d01-260.x

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results might highlight close relationships of the expression of CTLA‐4 and CD28 in terms of their cellular origins. Our results showing elevated cell surface expression of CD28 on CD8 + CD28 + cells in allergic asthmatic patients is in concordance with previous published results [43], thereby indicating that CD28 pathway plays a role in the development of allergic reactions. Moreover, the significant and negative correlation between GINA severity score and cell surface expression of CTLA‐4 and CD28 on PBMC indicated that there was a relationship between the progression of disease and the down‐regulation of the cell surface expression of co‐stimulatory receptors.…”

Section: Discussionsupporting

confidence: 93%

Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma

Wong

Lun

et al. 2005

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe co-stimulatory interactions of the B7 family molecules CD80 and CD86 on antigen-presenting cells, together with their T cell counter receptors CD28 and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), modulate T lymphocyte-mediated immune responses in a reciprocal manner. To investigate whether there is altered expression and the clinical significance of soluble costimulatory molecules in asthmatic patients, plasma concentrations of sCTLA-4, sCD28, sCD80 and sCD86 in 51 adult allergic asthmatic adults with or without steroid treatment, and 35 sex-and age-matched control subjects were measured by enzyme-linked immunosorbent assay (ELISA). Cell surface expression of CTLA-4 and CD28 on peripheral blood mononuclear cells (PBMC) were analysed by flow cytometry. Results showed that the plasma sCTLA-4 concentration was significantly higher in all asthmatic patients while sCD28 and sCD86 concentrations were significantly higher in steroid and non-steroid treated asthmatic patients, respectively, compared with control subjects (all P < < < < 0·01). Significantly increased cell surface expression of CD28 but not CTLA-4 on PBMC was found in asthmatic patients compared with controls ( P < < < < 0·05). The plasma concentration and cell surface expression of CTLA-4 were found to exhibit positive and significant correlations with those of CD28 (both P < < < < 0·05). Serum total IgE concentration correlated positively and significantly with sCTLA-4 and sCD28 concentrations in allergic asthmatic patients (both P < < < < 0·05). The increased expression of these soluble costimulatory molecules may reflect the dysregulation of T cell activation, thereby contributing to the immunopathogenesis of allergic asthma.

show abstract

Section: Discussionsupporting

confidence: 93%

Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma

Wong

Lun

et al. 2005

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…However, the ability of CD8+ T cells to regulate the production of IgE is a well‐recognized example of T‐cell mediated suppression (reviewed in 28), although the mechanisms are unclear. Furthermore, a study of adult venom allergic patients, reacting to hymenoptera stings, and controls showed a higher proportion of CD28 + cells within the CD8+, but not the CD4+ subset of the patients compared with controls (29). Interestingly, CD8+CD28‐ T cells are good producers of IFN‐γ (26) and have been suggested to have immunoregulatory properties (30).…”

Section: Discussionmentioning

confidence: 99%

Expression of the T‐cell markers CD2 and CD28 in healthy and atopic children during the first 18 months of life

Zdolsek

Jenmalm

2003

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Atopy may be associated with a reduced T-cell function early in life, particularly regarding maturation of Th1 responses. The T-cell surface molecules CD2 and CD28 are involved in important T-cell activation pathways. Stimulation via the CD2 receptor increases the responsiveness to interleukin (IL)-12, which is a potent inducer of Th1 responses, whereas CD28 stimulation is critical for Th2 differentiation. Our aim was to prospectively study the expression of the cell-surface markers CD2 and CD28 on T-cells in relation to development of atopic disease. Children (n = 172) were followed from birth to 18 months and the cumulative history of atopic disease was recorded. Blood samples were obtained at birth and at 18 months, and in a subgroup of 78 infants also at 3, 6 and 12 months. Flow cytometry was used to analyze the T-cell markers CD2 and CD28, the latter also within the subsets of T-helper (CD4+) and T-cytotoxic (CD8+) cells. At 18 months, 31 children had and 118 did not have atopic symptoms. At this age, skin prick test (SPT) positive children with atopic symptoms with or without an atopic family history (AFH) showed a lower expression of CD2 mode fluorescence intensity (FI) as well as a lower proportion of CD2+ cells, as compared with non-sensitized children with neither atopic symptoms nor AFH. This was accompanied by a higher expression of CD28 FI on CD2+CD8+CD28+ cells. No significant differences were seen at time points before 18 months, although the proportion of CD2+ tended to be low also earlier in life. In conclusion, the observed reduced expression of CD2 in atopic infants may support previous findings that atopy is associated with a reduced CD2 function. The high CD28 FI in SPT positive children with atopic symptoms may possibly be a consequence of a TH2-skewed immune system.

show abstract

“…[9,35,36]. Tsicopoulos et al described that CD28 is expressed at higher levels on peripheral blood T cells from patients who are allergic to bee venom than from those of control individuals [37]. The level of CD28 expression on CD4 1 CD45RO 1 T cells is increased when peripheral blood mononuclear cells (PBMC) from patients with perennial rhinitis are cultured with mite antigen [22].…”

Section: Discussionmentioning

confidence: 99%

Expression of costimulatory CD80/CD86‐CD28/CD152 molecules in nasal mucosa of patients with perennial allergic rhinitis

Hattori¹,

Okano²,

Yoshino³

et al. 2001

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy

Abstract: These results suggest that the CD28 pathway is probably involved in the development of allergic reactions, but at least at the phenotypic level, CD28 expression remained unchanged after rush venom immunotherapy.

Cited by 4 publications

References 25 publications

Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma

Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma

Expression of the T‐cell markers CD2 and CD28 in healthy and atopic children during the first 18 months of life

Expression of costimulatory CD80/CD86‐CD28/CD152 molecules in nasal mucosa of patients with perennial allergic rhinitis

Contact Info

Product

Resources

About